Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMS2M7O)

• Drug Name: Deferiprone Drug Info
• Synonyms: Ferriprox (TN)

Indication

Disease Entry	ICD 11	Status	REF
Beta thalassemia	3A50.2	Approved	[1]
Iron overload disease	5C64.10	Approved	[1]
Thalassemia	3A50	Approved	[2]

• Cross-matching ID:
  PubChem CID: 2972
  ChEBI ID: CHEBI:68554
  CAS Number: CAS 30652-11-0
  TTD Drug ID: DMS2M7O
  INTEDE Drug ID: DR1762
  ACDINA Drug ID: D00173

Molecule-Related Drug Atlas

Drug(s) Targeting Iron (Fe)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Etidronate Disodium	DMAWJIN	Osteoporosis	FB83.0	Approved	[7]
Deferoxamine Mesylate	DMTUKZH	Acute iron or aluminum toxicity	FB83.20	Approved	[7]
Exjade	DMHPRWG	Iron overload disease	5C64.10	Approved	[8]
Soluble ferric pyrophosphate	DMLAYTP	Iron-deficiency anemia	3A00	Phase 3	[9]
SPD602	DMKJ9LU	Anemia	3A00-3A9Z	Phase 2	[10]
Monohydroxyethylrutoside	DMAQJHO	Cardiovascular disease	BA00-BE2Z	Phase 1	[11]
DpC	DM4ZDOE	Solid tumour/cancer	2A00-2F9Z	Phase 1	[12]

Drug(s) Metabolized By UDP-glucuronosyltransferase 1A6 (UGT1A6)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[13]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[14]
Mycophenolate mofetil	DMPQAGE	Hepatosplenic T-cell lymphoma		Approved	[15]
Propofol	DMB4OLE	Anaesthesia	9A78.6	Approved	[16]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[17]
Aspirin	DM672AH	Acute coronary syndrome	BA41	Approved	[18]
Naproxen	DMZ5RGV	Bursitis		Approved	[19]
ANDROSTERONE	DMITJAK	N. A.	N. A.	Phase 3	[20]
BCP-13498	DM2BO9W	N. A.	N. A.	Phase 2	[21]
LM-94	DMW3QGJ	N. A.	N. A.	Phase 1/2	[22]

Drug(s) Affected By Frataxin, mitochondrial (FXN)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[23]
Molsidomine	DM9MA8O	Angina pectoris	BA40	Approved	[5]
Betamethasone	DMAHJEF	Acute adrenal insufficiency		Approved	[5]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[24]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[25]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[26]
Ethanol	DMDRQZU	Chronic pain	MG30	Approved	[27]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[28]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[29]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[30]

Drug(s) Affected By Serotransferrin (TF)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ethanol	DMDRQZU	Chronic pain	MG30	Approved	[31]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[32]
Chlorpromazine	DMBGZI3	Acute intermittent hepatic porphyria	5C58.11	Approved	[33]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[34]
Isoflurophate	DMBSK7X	Glaucoma/ocular hypertension	9C61	Approved	[35]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[36]
Rosiglitazone	DMILWZR	Chronic kidney disease	GB61	Approved	[37]
Amiodarone	DMUTEX3	Tachyarrhythmias	BC71	Approved	[38]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[39]
Clofibrate	DMPC1J7	Dysbetalipoproteinemia	5C80.2	Approved	[40]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Iron (Fe)	TTUDR0C	NOUNIPROTAC	Modulator	[3]

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
UDP-glucuronosyltransferase 1A6 (UGT1A6) Main DME	DESD26P	UD16_HUMAN	Substrate	[4]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Frataxin, mitochondrial (FXN)	OTE9U09A	FRDA_HUMAN	Gene/Protein Processing	[5]
Serotransferrin (TF)	OT41PEMS	TRFE_HUMAN	Gene/Protein Processing	[6]

References

• [1] Deferiprone FDA Label
• [2] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7456).
• [3] 2011 FDA drug approvals. Nat Rev Drug Discov. 2012 Feb 1;11(2):91-4.
• [4] Deferiprone glucuronidation by human tissues and recombinant UDP glucuronosyltransferase 1A6: an in vitro investigation of genetic and splice variants. Drug Metab Dispos. 2009 Feb;37(2):322-9.
• [5] Pharmacological screening using an FXN-EGFP cellular genomic reporter assay for the therapy of Friedreich ataxia. PLoS One. 2013;8(2):e55940.
• [6] Antiproliferative effect of deferiprone on the Hep G2 cell line. Biochem Pharmacol. 1998 Aug 15;56(4):431-7. doi: 10.1016/s0006-2952(98)00071-9.
• [7] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [8] Deferasirox : a review of its use in the management of transfusional chronic iron overload. Drugs. 2007;67(15):2211-30.
• [9] A micronised, dispersible ferric pyrophosphate with high relative bioavailability in man. Br J Nutr. 2004 Jan;91(1):107-12.
• [10] ClinicalTrials.gov (NCT01604941) Pharmacokinetics of SSP-004184 in the Treatment of Chronic Iron Overload Requiring Chelation Therapy. U.S. National Institutes of Health.
• [11] Monohydroxyethylrutoside, a dose-dependent cardioprotective agent, does not affect the antitumor activity of doxorubicin. Clin Cancer Res. 1997 Oct;3(10):1747-54.
• [12] Anticancer Thiosemicarbazones: Chemical Properties, Interaction with Iron Metabolism, and Resistance Development. Antioxid Redox Signal. 2019 Mar 10;30(8):1062-1082.
• [13] UGT1A6 and UGT2B15 polymorphisms and acetaminophen conjugation in response to a randomized, controlled diet of select fruits and vegetables. Drug Metab Dispos. 2011 Sep;39(9):1650-7.
• [14] UDP glucuronosyltransferase (UGT) 1A6 pharmacogenetics: II. Functional impact of the three most common nonsynonymous UGT1A6 polymorphisms (S7A, T181A, and R184S). J Pharmacol Exp Ther. 2005 Jun;313(3):1340-6.
• [15] Characterization of rat intestinal microsomal UDP-glucuronosyltransferase activity toward mycophenolic acid. Drug Metab Dispos. 2006 Sep;34(9):1632-9.
• [16] Pharmacokinetics of propofol and extrahepatic UGT1A6 gene expression in anhepatic rats. Pharmacology. 2009;84(4):219-26.
• [17] Troglitazone glucuronidation in human liver and intestine microsomes: high catalytic activity of UGT1A8 and UGT1A10. Drug Metab Dispos. 2002 Dec;30(12):1462-9.
• [18] Polymorphisms of Aspirin-Metabolizing Enzymes CYP2C9, NAT2 and UGT1A6 in Aspirin-Intolerant Urticaria. Allergy Asthma Immunol Res. 2011 Oct;3(4):273-6.
• [19] S-Naproxen and desmethylnaproxen glucuronidation by human liver microsomes and recombinant human UDP-glucuronosyltransferases (UGT): role of UGT2B7 in the elimination of naproxen. Br J Clin Pharmacol. 2005 Oct;60(4):423-33.
• [20] Structural and functional studies of UDP-glucuronosyltransferases. Drug Metab Rev. 1999 Nov;31(4):817-99.
• [21] Human UGT1A6 pharmacogenetics: identification of a novel SNP, characterization of allele frequencies and functional analysis of recombinant allozymes in human liver tissue and in cultured cells. Pharmacogenetics. 2004 Aug;14(8):487-99.
• [22] Identification of aspartic acid and histidine residues mediating the reaction mechanism and the substrate specificity of the human UDP-glucuronosyltransferases 1A. J Biol Chem. 2007 Dec 14;282(50):36514-24.
• [23] Transcriptional and Metabolic Dissection of ATRA-Induced Granulocytic Differentiation in NB4 Acute Promyelocytic Leukemia Cells. Cells. 2020 Nov 5;9(11):2423. doi: 10.3390/cells9112423.
• [24] Integrative "-Omics" analysis in primary human hepatocytes unravels persistent mechanisms of cyclosporine A-induced cholestasis. Chem Res Toxicol. 2016 Dec 19;29(12):2164-2174.
• [25] Human embryonic stem cell-derived test systems for developmental neurotoxicity: a transcriptomics approach. Arch Toxicol. 2013 Jan;87(1):123-43.
• [26] Quantitative proteomics reveals a broad-spectrum antiviral property of ivermectin, benefiting for COVID-19 treatment. J Cell Physiol. 2021 Apr;236(4):2959-2975. doi: 10.1002/jcp.30055. Epub 2020 Sep 22.
• [27] Oxidative stress-dependent frataxin inhibition mediated alcoholic hepatocytotoxicity through ferroptosis. Toxicology. 2020 Dec 1;445:152584. doi: 10.1016/j.tox.2020.152584. Epub 2020 Oct 2.
• [28] Activation of AIFM2 enhances apoptosis of human lung cancer cells undergoing toxicological stress. Toxicol Lett. 2016 Sep 6;258:227-236.
• [29] Increased mitochondrial ROS formation by acetaminophen in human hepatic cells is associated with gene expression changes suggesting disruption of the mitochondrial electron transport chain. Toxicol Lett. 2015 Apr 16;234(2):139-50.
• [30] Bringing in vitro analysis closer to in vivo: studying doxorubicin toxicity and associated mechanisms in 3D human microtissues with PBPK-based dose modelling. Toxicol Lett. 2018 Sep 15;294:184-192.
• [31] Cardiac toxicity from ethanol exposure in human-induced pluripotent stem cell-derived cardiomyocytes. Toxicol Sci. 2019 May 1;169(1):280-292.
• [32] Global gene expression analysis reveals differences in cellular responses to hydroxyl- and superoxide anion radical-induced oxidative stress in caco-2 cells. Toxicol Sci. 2010 Apr;114(2):193-203. doi: 10.1093/toxsci/kfp309. Epub 2009 Dec 31.
• [33] Copper-stimulated endocytosis and degradation of the human copper transporter, hCtr1. J Biol Chem. 2003 Mar 14;278(11):9639-46. doi: 10.1074/jbc.M209455200. Epub 2002 Dec 25.
• [34] Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. Toxicol Sci. 2010 May;115(1):66-79.
• [35] Tyrosines of human and mouse transferrin covalently labeled by organophosphorus agents: a new motif for binding to proteins that have no active site serine. Toxicol Sci. 2009 Jan;107(1):144-55. doi: 10.1093/toxsci/kfn211. Epub 2008 Oct 16.
• [36] Definition of transcriptome-based indices for quantitative characterization of chemically disturbed stem cell development: introduction of the STOP-Toxukn and STOP-Toxukk tests. Arch Toxicol. 2017 Feb;91(2):839-864.
• [37] Proteomic analysis of human adipose tissue after rosiglitazone treatment shows coordinated changes to promote glucose uptake. Obesity (Silver Spring). 2010 Jan;18(1):27-34. doi: 10.1038/oby.2009.208. Epub 2009 Jun 25.
• [38] Capturing time-dependent activation of genes and stress-response pathways using transcriptomics in iPSC-derived renal proximal tubule cells. Cell Biol Toxicol. 2023 Aug;39(4):1773-1793. doi: 10.1007/s10565-022-09783-5. Epub 2022 Dec 31.
• [39] Physiological and toxicological transcriptome changes in HepG2 cells exposed to copper. Physiol Genomics. 2009 Aug 7;38(3):386-401.
• [40] Effect of clofibrate on plasma proteins including components of the hemostatic mechanism. Clin Chim Acta. 1976 Jan 2;66(1):9-17. doi: 10.1016/0009-8981(76)90366-1.